Top Pharmaceutical Stocks To Watch Now - November 17th

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • SELLAS Life Sciences Group (SLS) was the standout mover, rising $12.20 to $19.67 on nearly 90 million shares traded. Its lead cancer immunotherapy, galinpepimut-S, is in Phase 3 trials for acute myeloid leukemia.
  • Eli Lilly (LLY) shares fell $16.65 to $1,415.02. The $1.33 trillion pharmaceutical company markets treatments including Mounjaro and Zepbound.
  • Johnson & Johnson (JNJ) declined $2.71 to $279.84. It operates in Innovative Medicine and MedTech, with its medicine business spanning areas including oncology, immunology, and neuroscience.
  • Interested in SELLAS Life Sciences Group? Here are five stocks we like better.

SELLAS Life Sciences Group, Eli Lilly and Company, and Johnson & Johnson are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell medicines and related treatments. For investors, their value can be influenced by factors such as clinical-trial results, regulatory approvals, patent protection, drug demand, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

SELLAS Life Sciences Group (SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

Shares of NASDAQ:SLS traded up $12.20 during midday trading on Tuesday, hitting $19.67. 89,964,876 shares of the company's stock were exchanged, compared to its average volume of 8,232,931. The company has a market cap of $3.97 billion, a PE ratio of -98.36 and a beta of 2.73. The stock has a 50 day moving average price of $10.90 and a 200-day moving average price of $8.79. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $24.89.

Read Our Latest Research Report on SLS

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY stock traded down $16.65 during trading on Tuesday, hitting $1,415.02. The company's stock had a trading volume of 1,126,930 shares, compared to its average volume of 2,950,144. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,475.25. The business has a fifty day moving average of $1,247.93 and a 200-day moving average of $1,112.33. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.33 trillion, a PE ratio of 45.91, a P/E/G ratio of 1.71 and a beta of 0.40.

Read Our Latest Research Report on LLY

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

NYSE JNJ traded down $2.71 on Tuesday, hitting $279.84. 2,204,532 shares of the stock traded hands, compared to its average volume of 7,926,807. The business's fifty day moving average is $267.12 and its two-hundred day moving average is $250.12. Johnson & Johnson has a 12 month low of $198.53 and a 12 month high of $290.25. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm has a market capitalization of $673.66 billion, a price-to-earnings ratio of 42.40, a PEG ratio of 2.80 and a beta of 0.22.

Read Our Latest Research Report on JNJ

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines